Compare DexCom, Inc. (DXCM) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kroger Co — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while Kroger Co trades at $58.71 (market cap $34.65B). The key difference: Kroger Co is the larger of the two by market cap, and Kroger Co pays a 2.24% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | KR | |
|---|---|---|
Market Cap | $28.06B | $34.65B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $75.60 |
52-Week Low | $54.84 | $55.53 |
Enterprise Value | $27.03B | $54.75B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Kroger (KR) trades at $57.92, down 1.4% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows a high P/E of 55.29 but a low P/S of 0.28, with recent earnings beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company's $1.65 billion acquisition of Giant Eagle aims to expand its Midwest footprint, while cash flow trends remain volatile with a net cash flow of $2.08 billion in 2025.
The outlook is cautiously optimistic, supported by analyst consensus of $68.63 and a 47.72% buy rating, but risks include rising debt-to-asset ratios and competitive pressures. Near-term performance hinges on execution of the Giant Eagle integration and Q2 2026 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
